ORIGINAL ARTICLESIMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE☆
References (6)
J. Path. Bact.
(1965)- et al.
Am. J. Path.
(1963)
There are more references available in the full text version of this article.
Cited by (277)
Nanoengineered coordination polymers boost cancer immunotherapy
2023, Materials TodayCancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review
2022, JACC: CardioOncologyCitation Excerpt :Pexidartinib is associated with hypertension (Table 1); cardiovascular toxicities of other myeloid depletion strategies remain unknown. Although predicted as a potential antitumor treatment modality more than 50 years ago,170 clinically tractable cancer immunotherapies have become a reality only in the past decade. This achievement is based on many decades of research advances elucidating basic mechanisms of both immunity and tumorigenesis.
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
2022, Seminars in Cancer BiologyThe role of B cells in the development, progression, and treatment of lymphomas and solid tumors
2022, Advances in Immunology
- ☆
The Roy Cameron Memorial Lecture of the College of Pathologists, delivered in London on May 10, 1967.
Copyright © 1967 Published by Elsevier Ltd.